Allergan Memantine Filing Delay Anticipated Following Phase III Results
This article was originally published in The Pink Sheet Daily
Company awaits results from a second trial evaluating the neuroprotective agent in prevention of vision loss.
You may also be interested in...
Firm gains FDA approval of treatment to reduce elevated intraocular pressure after three “approvable” letters.
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.